Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation

NCT02942173 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.

NCT NCT02942173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02942173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2016
Completion date
August 21, 2020
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease, gvhd, leukemia, lymphoma, myelodysplastic syndromes, opportunistic infections